DrugDashboards

Pantoprazole sodium

Pantoprazole sodium · PANTOPRAZOLE SODIUM 40 mg/10mL · Injection, Powder, For Solution · Intravenous · BE Pharmaceuticals Inc.

NDC 71839-0122-01 · 1 VIAL in 1 CARTON / 10 mL in 1 VIAL · ANDA · View full market →

The short version

13 companies supply this market — deep enough that no single failure threatens the supply. Historically, drugs in this position went on to a new shortage within 90 days about 0.7% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$8.50
Reported to Texas DSHS · 2023 annual filing · BE Pharmaceuticals Inc

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$152
25 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.7%chance of a new FDA shortage posting for pantoprazole sodium (injectable) in the next 90 days

sterile injectable · price up 28% YoY · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $12.94 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA216171
TE code
AP
Approval date
May 18, 2022
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedSep 5, 2023
    BE PHARMACEUTICALS AG — Lack of Assurance of Sterility: Powder discoloration due to small crack in some vials.

Manufacturers of Pantoprazole sodium (Injection, Powder, For Solution)

LabelerStrengthFirst seenLast seen
Meitheal Pharmaceuticals Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 3, 2026
BE Pharmaceuticals Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.PANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Devatis Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Eugia US LLCPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Northstar Rx LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Novadoz Pharmaceuticals LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Piramal Critical CarePANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Sandoz IncPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Takeda GmbHPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Wasserburger Arzneimittelwerk GmbHPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Pantoprazole sodium — NDC 71839-0122-01," retrieved September 3, 2026, https://drugdashboards.com/drug/71839012201.

Free to cite with attribution — see how the data is put together.